Targeted drug combinations for T-cell acute lymphoblastic leukemia that returned or did not respond
Tests targeted drug combinations in people whose T-cell acute lymphoblastic leukemia relapsed or resisted treatment.
Key facts
- Who runs it
- Centre Hospitalier De Versailles
- Where
- Aix En Provence, Amiens Cedex 1, Angers, Argenteuil Cedex, Avignon, Bayonne, Besancon Cedex, Bobigny, Brest, Caen, Castelnauv Le Lez, Clamart, Clermont-Ferrand, Corbeil Essonnes Cedex, Creteil, Dijon, Dunkirk Cedex 1, Epagny Metz-tessy, Grenoble Cedex 09, Le Chesnay Rocquencourt, Lille Cedex, Limoges Cedex 1, Marseille, Metz Cedex 03, Montpellier Cedex 5, Mulhouse, Nantes, Nice, Nîmes, Orleans Cedex 2, Paris, Paris Cedex 12, Paris Cedex 13, Perpignan Cedex, Pessac, Pierre-Bénite, Poitiers, Reims Cedex, Rennes, Roubaix, Rouen, Saint-Priest-en-Jarez, Toulouse Cedex 9, Tours Cedex 9, Vandoeuvre Les Nancy, and Villejuif, FranceSee the 51 sitesAlso in 4 other countries, 16 sites
- Trial code
- Registry title
- A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 86 people, planned
- Started
- 1 Jun 2026
- Expected to end
- 1 Jan 2030
- Type of study
- Interventional
- Record updated
- 8 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 15 or older with T-cell acute lymphoblastic leukemia that came back (first or second relapse) or did not respond to treatment.
- Age
- 15 years or older (in France, people under 18 need both parents to sign consent).
- Sex
- All sexes can join.
- Disease stage
- T-cell acute lymphoblastic leukemia in first or second relapse, or refractory. A first relapse counts only if it came within 24 months after complete remission and nelarabine is not seen as a good option. Later relapses can join. Refractory means no response after at least 2 lines of chemotherapy. Relapse after transplant or CAR-T cells can join.
- Earlier treatment
- Refractory patients must have had at least 2 lines of chemotherapy. Relapse after transplant or CAR-T cell treatment is allowed. No live or live-attenuated vaccine in the 4 weeks before the first dose of study treatment.
- Biomarker or test result
- Blast cells in blood or bone marrow must be sent to one of 3 reference laboratories (France, Spain, The Netherlands), or a recent test done within 10 days before inclusion. At least one targeted treatment option must be validated by a national committee.
Main reasons for not taking part
- Late relapse more than 24 months after complete remission
- Relapse outside the bone marrow only, or symptomatic central nervous system involvement
- Pregnant or breastfeeding women
- Known active HBV, HCV or HIV disease
- Another active uncontrolled cancer, or taking part in another trial with an investigational drug
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Patients aged 15y or more (under 18y only for France)
- Signed informed consent for patients aged ≥ 18 years and signed informed consent from both parents for patients aged between ≥ 15 years and < 18 years (only for France)
- Patients with T-cell acute lymphoblastic leukemia in first or second relapse or in the refractory phase. a) Patients with first relapses are eligible if relapse occurred within 24 months post complete remission achievement and if nelarabine is not considered as appropriate salvage therapy. b) Patients with second and all subsequent relapses are eligible. c) Refractory patients are defined as patients not responding after at least 2 lines of chemotherapy (induction + salvage). d) Patients with relapses post-transplant and post CART-cells treatments are eligible
- Blast cells in blood and/or bone marrow to allow the shipment to one of the 3 reference laboratories in France, Spain and The Netherlands or An informative biological assessment already performed within 10 days prior to inclusion in one of the three reference laboratories in France, Spain or The Netherlands with at least one targeted therapeutic option validated (TTO1, venetoclax + tofacitinib; TTO2, venetoclax+ everolimus + enrylaze; TTO3, venetoclax + 5-azacytidine) by one of the three National Validation Committees
- Adequate ECOG score (0-3)
- Patients must be affiliated to a National Health systems (see country-based specificity)
- Patients must not have a contra-indication for venetoclax, tofacitinib, everolimus, glutaminolytic agents (enrylaze) or 5-azacytidine
- Willingness of women of child-bearing potential (WOCBP) or of male patients whose sexual partners are WOCBP to use an effective form of contraception during the study and at least 3 months thereafter (see Annex 13.9)
Who cannot take part
- Administration of live or live-attenuated vaccines within 4 weeks prior to the first dose of study treatment (see Annex 13.10)
- Participation in another clinical trial with an investigative drug at the time of study enrolment
- Subject presenting with psychiatric disorders or any other condition that impair their ability to cooperate with study procedures
- Individuals with another active uncontrolled malignancy
- Known active HBV-, HCV and HIV related diseases
- Patients with contra-indication to chemotherapy except if considered related to the ALL: • ASAT (SGOT) and/or ALAT (SGPT) > 5 x ULN • Total bilirubin ≥ 2.5 x ULN • Estimated glomerular filtration rate (GFR) < 50 mL/mn using the MDRD equation
- Patients in palliative care
- Patients with late relapses after the first complete remission (> 24 months post complete remission)
- Patients with extramedullary only relapses or with clinically symptomatic central nervous system (CNS) involvement
- Pregnant or lactating women
- Patient under curatorship or deprived of liberty (except for minors)
Where in France
Also in 4 other countries, 16 sites
- Centre Hospitalier Du Pays D Aix Centre Hospitalier Intercommunal Aix-PertuisAix En Provence, FranceNot yet recruiting
- Centre Hospitalier Universitaire Amiens PicardieAmiens Cedex 1, FranceNot yet recruiting
- Centre Hospitalier Universitaire D'AngersAngers, FranceNot yet recruiting
- Centre Hospitalier Victor DupouyArgenteuil Cedex, FranceNot yet recruiting
- Centre Hospitalier d'AvignonAvignon, FranceNot yet recruiting
- Centre Hospitalier de la Cote BasqueBayonne, FranceNot yet recruiting
- CHU BesanconBesancon Cedex, FranceNot yet recruiting
- Hopital AvicenneBobigny, FranceNot yet recruiting
- Centre Hospitalier Régional et Universitaire de BrestBrest, FranceNot yet recruiting
- Centre Hospitalier Universitaire de Caen NormandieCaen, FranceNot yet recruiting
- Clinique Du ParcCastelnauv Le Lez, FranceNot yet recruiting
- Hopital D Instruction Des Armées PercyClamart, FranceNot yet recruiting
- University Hospital Of Clermont-FerrandClermont-Ferrand, FranceNot yet recruiting
- Centre Hospitalier Sud FrancilienCorbeil Essonnes Cedex, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisCreteil, FranceNot yet recruiting
- Centre Hospitalier Universitaire de DijonDijon, FranceNot yet recruiting
- L’Hopital Alexandra LepeveDunkirk Cedex 1, FranceNot yet recruiting
- Centre Hospitalier Annecy GenevoisEpagny Metz-tessy, FranceNot yet recruiting
- Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 09, FranceNot yet recruiting
- Centre Hospitalier De VersaillesLe Chesnay Rocquencourt, FranceNot yet recruiting
- Centre Hospitalier Universitaire De LilleLille Cedex, FranceNot yet recruiting
- Centre Hospitalier Et Universitaire De LimogesLimoges Cedex 1, FranceNot yet recruiting
- Assistance Publique Hopitaux de Marseille (AP-HM) - Hôpital La ConceptionMarseille, FranceNot yet recruiting
- Institut Paoli-CalmettesMarseille, FranceNot yet recruiting
- Centre Hospital Region Metz ThionvilleMetz Cedex 03, FranceNot yet recruiting
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceNot yet recruiting
- Groupe Hospitalier de la Région de Mulhouse et Sud AlsaceMulhouse, FranceNot yet recruiting
- Centre Hospitalier Universitaire de NantesNantes, FranceNot yet recruiting
- Centre Hospitalier Universitaire de NiceNice, FranceNot yet recruiting
- Centre Hospitalier Universitaire de NîmesNîmes, FranceNot yet recruiting
- Centre Hospitalier Universitaire D OrleansOrleans Cedex 2, FranceNot yet recruiting
- Assistance Publique Hopitaux de ParisParis, FranceNot yet recruiting
- Hopital Necker Enfants MaladesParis, FranceNot yet recruiting
- Hopital Saint LouisParis, FranceNot yet recruiting
- Robert Debre University HospitalParis, FranceNot yet recruiting
- Trousseau HospitalParis, FranceNot yet recruiting
- Hopital Saint AntoineParis Cedex 12, FranceNot yet recruiting
- Hopitaux Universitaires Pitie SalpetriereParis Cedex 13, FranceNot yet recruiting
- Centre Hospitalier De PerpignanPerpignan Cedex, FranceNot yet recruiting
- Centre Hospitalier Universitaire de BordeauxPessac, FranceNot yet recruiting
- Hospices Civils de LyonPierre-Bénite, FranceNot yet recruiting
- Centre Hospitalier Universitaire de PoitiersPoitiers, FranceNot yet recruiting
- Centre Hospitalier Universitaire ReimsReims Cedex, FranceNot yet recruiting
- Centre Hospitalier Universitaire de RennesRennes, FranceNot yet recruiting
- Centre hospitalier de RoubaixRoubaix, FranceNot yet recruiting
- Centre Hospitalier Universitaire RouenRouen, FranceNot yet recruiting
- Centre Hospitalier Universitaire de Saint EtienneSaint-Priest-en-Jarez, FranceNot yet recruiting
- Centre Hospitalier Universitaire De ToulouseToulouse Cedex 9, FranceNot yet recruiting
- Centre Hospitalier Regional Universitaire De ToursTours Cedex 9, FranceNot yet recruiting
- CHRU De NancyVandoeuvre Les Nancy, FranceNot yet recruiting
- Institut Gustave RoussyVillejuif, FranceNot yet recruiting
About the trial
What the trial wants to find out
Evaluer le bénéfice d’une stratégie basée sur la médecine de précision (combinaisons de traitements ciblés (CTC)) sur le taux de réponse hématologique chez des patients atteints de leucémie aiguë lymphoblastique T en rechute ou réfractaire.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
- Plain-language title
- Targeted drug combinations for T-cell acute lymphoblastic leukemia that returned or did not respondGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 8 June 2026